ACR Convergence 2025| Tips for Starting Your Own Rheumatology Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: liver

How to Diagnose Antisynthetase Syndrome

How to Diagnose Antisynthetase Syndrome

Quretul Quresh, MD, & Stephen Lindsey, MD  |  March 17, 2017

Antisynthetase syndrome (AS) is strongly associated with the presence of antibodies to aminoacyl-transfer RNA (tRNA) synthetases (ARSs) that are implicated in the pathogenesis of myositis and interstitial lung disease (ILD). Antibodies against eight antisynthetases have been identified and are detected in 16–26% of patients with idiopathic inflammatory myopathies (IIM).1 Serum assays for five of these…

Filed under:ConditionsMyositisOther Rheumatic ConditionsResearch Rheum Tagged with:aminoacyl-transfer RNAAntisynthetase SyndromeClinicalDiagnosisinflammatoryInterstitial Lung DiseaseMyopathiesmyositisoutcomepatient careResearchrheumatologistrheumatologysyndromeTreatment

RheumPAC Committee Outlines Goals for 2017

From the College  |  March 17, 2017

“You can’t win last night’s game again.” —George Karl, professional basketball player and coach Amid the angst and upheaval from our recent elections and associated uncertainty for future healthcare policies, one thing remains clear: We must increase our engagement with our elected officials to educate them on the needs of our profession and our patients….

Filed under:From the College Tagged with:Advocacygoalspolitical action committeerheumatologyRheumPAC

Time to Rethink Inpatient Rehab After Knee Replacement?

Megan Brooks  |  March 14, 2017

NEW YORK (Reuters Health)—Inpatient rehabilitation did not lead to better mobility following total knee replacement compared with a home-based program in a randomized controlled trial (RCT) conducted in Australia. The findings do not support inpatient rehabilitation for adults undergoing uncomplicated total knee arthroplasty, conclude the authors in JAMA on March 14.1 “Normally, one study is…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:kneeknee arthroplastyrehabilitationtotal knee replacement

Brodalumab Approved for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  March 9, 2017

Brodalumab has received FDA approval for treating plaque psoriasis in adults, with a Boxed Warning against prescribing it for patients with a history of suicidal thoughts or behavior…

Filed under:Biologics/DMARDsDrug Updates Tagged with:brodalumabFDAFood and Drug Administrationplaque psoriasis

ACR Puts Forward Principles on Patient Access to Care

Mary Beth Nierengarten  |  March 1, 2017

As the 115th Congress and the Trump administration consider potential reforms to the healthcare system, including actions related to the Affordable Care Act (ACA), physicians around the country remain vitally concerned about the need to preserve and improve access to care for their patients. To that end, the ACR continues to lobby for policies that…

Filed under:Legislation & AdvocacyPractice SupportProfessional Topics Tagged with:Access to carechronic arthritishealthcare coveragehealthcare provisionsongoing careposition statementrheumatic diseases

ACR Releases New Position Statements on Site of Service & Compounding

Mary Beth Nierengarten  |  March 1, 2017

Patient Safety & Site of Service for Biologics Although emphasizing its strong support for the use of biologic agents as necessary treatments for rheumatic diseases, the ACR Board of Directors continues to be concerned about the safe delivery of these agents, given the potential for associated adverse events and infusion reactions. In a position statement…

Filed under:Biologics/DMARDsLegislation & Advocacy Tagged with:biologic infusionsdrug compoundingposition statementquinacrine

Online Treatment Reduces Chronic Knee Pain from Arthritis

Shereen Lehman  |  February 22, 2017

(Reuters Health)—A web-based program of exercise and coping skills training improves both function and pain in arthritic knees, a new study suggests. This kind of online therapy can greatly improve access to effective, nonsurgical and non-drug relief for people with osteoarthritis of the knee, researchers say. “Osteoarthritis is a leading cause of chronic knee pain…

Filed under:ConditionsOsteoarthritis and Bone DisordersProfessional Topics Tagged with:Arthritisknee painonline therapyPainCOACHtelemedicine

Switch to Biosimilar Infliximab for IBD Slashes Drug Costs

Reuters Staff  |  February 17, 2017

NEW YORK—Inflammatory bowel disease (IBD) patients can be safely switched from originator infliximab to biosimilar infliximab using a managed-switching program, U.K. research shows. “Thus far, there does not appear to be any significant difference between the two infliximab products in terms of drug persistence, side effects, adverse reactions, disease activity, or blood tests, but ongoing…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsCT-P13drug costsIBDinfliximab

Quality Update Reporting Changes under MACRA

Mary Beth Nierengarten  |  February 16, 2017

With the termination of the Sustainable Growth Rate formula through the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), clinicians who participate in Medicare Part B will now be reimbursed through a new payment model called the Quality Payment Program (QPP). How It Works The QPP rewards the delivery of high-quality patient care via…

Filed under:Practice SupportProfessional Topics Tagged with:Advanced Alternative Payment MethodMedicare Access and CHIP Reauthorization Act of 2015 (MACRA)Medicare Part BMIPSQuality Payment Program (QPP)Quality Update Reportingsustainable growth rate formula

ACR Urges CMMI to Test Transparently: Coalition offers principles to guide CMS’s care innovation efforts

Susan Bernstein  |  February 16, 2017

The Center for Medicare and Medicaid Innovation (CMMI), which develops concepts for healthcare payment and service delivery, must be transparent and engaged with all stakeholders as it tests new models, according to a coalition of 30 associations. On Feb. 10, the Healthcare Leaders for Accountable Innovation in Medicare Coalition, which includes the ACR, released six…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Center for Medicare and Medicaid Innovation (CMMI)CMMIguideline principlesHealthcare Leaders for Accountable Innovation in Medicare CoalitionMACRAMedicare Access and CHIP Reauthorization Act of 2015Quality Payment Program

  • « Previous Page
  • 1
  • …
  • 71
  • 72
  • 73
  • 74
  • 75
  • …
  • 127
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences